Online inquiry

IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1232MR)

This product GTTS-WQ1232MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TPBG gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Non-small lung carcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001166392.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7162
UniProt ID Q13641
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1232MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3164MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ12765MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ8537MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ1326MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ12346MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ9583MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ10587MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ9955MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KBSA301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW